PL435261A1 - Peptyd do stosowania w leczeniu lub zapobieganiu COVID-19 - Google Patents

Peptyd do stosowania w leczeniu lub zapobieganiu COVID-19

Info

Publication number
PL435261A1
PL435261A1 PL435261A PL43526120A PL435261A1 PL 435261 A1 PL435261 A1 PL 435261A1 PL 435261 A PL435261 A PL 435261A PL 43526120 A PL43526120 A PL 43526120A PL 435261 A1 PL435261 A1 PL 435261A1
Authority
PL
Poland
Prior art keywords
treatment
covid
peptide
prevention
cov
Prior art date
Application number
PL435261A
Other languages
English (en)
Inventor
Norbert Odolczyk
Piotr Zielenkiewicz
Ewa Marzec
Jarosław Poznański
Original Assignee
Instytut Biochemii I Biofizyki Polskiej Akademii Nauk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Instytut Biochemii I Biofizyki Polskiej Akademii Nauk filed Critical Instytut Biochemii I Biofizyki Polskiej Akademii Nauk
Priority to PL435261A priority Critical patent/PL435261A1/pl
Publication of PL435261A1 publication Critical patent/PL435261A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/14—Angiotensins: Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/085—Angiotensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Vascular Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Przedmiotem zgłoszenia są peptydy nadające się do blokowania interakcji pomiędzy glikoproteiną S wirusa SARS-CoV-2, a ludzkim receptorem ACE2, zwłaszcza w celu leczenia, bądź wspomagania leczenia infekcji wywołanej wirusem SARS-COV-2 i/lub wirusami wykazującymi wysokie podobieństwo sekwencyjnie genomu do wirusa SARS-CoV-2.
PL435261A 2020-09-10 2020-09-10 Peptyd do stosowania w leczeniu lub zapobieganiu COVID-19 PL435261A1 (pl)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL435261A PL435261A1 (pl) 2020-09-10 2020-09-10 Peptyd do stosowania w leczeniu lub zapobieganiu COVID-19

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL435261A PL435261A1 (pl) 2020-09-10 2020-09-10 Peptyd do stosowania w leczeniu lub zapobieganiu COVID-19

Publications (1)

Publication Number Publication Date
PL435261A1 true PL435261A1 (pl) 2022-03-14

Family

ID=80629051

Family Applications (1)

Application Number Title Priority Date Filing Date
PL435261A PL435261A1 (pl) 2020-09-10 2020-09-10 Peptyd do stosowania w leczeniu lub zapobieganiu COVID-19

Country Status (1)

Country Link
PL (1) PL435261A1 (pl)

Similar Documents

Publication Publication Date Title
MX2023000411A (es) Vacuna combinada de sars-cov-2 e influenza.
MX392533B (es) Anticuerpos humanos contra glicoproteina del virus ebola.
EA201390806A1 (ru) Конструкция пептидного каркаса
JOP20220349A1 (ar) توليفة لقاح ضد الإصابة بفيروس مخلوي تنفسي
MX2011007195A (es) Derivado de ciclosporina para el uso en el tratamiento de infección de virus de hepatitis c (vhc) y virus de inmunodeficiencia humana (vih).
TR200200838T2 (tr) İmmunolojik olarak önemli herpes simpleks virüs antijenleri.
MX2019006943A (es) Polipéptidos para manejo de infecciones virales.
EP2552490A4 (en) INFLUENZA MATRIX 2 PROTEIN ECKTOMOMAS, EXPRESSION SYSTEM THEREFOR AND USES THEREOF
EA202193119A1 (ru) Профилактическое лечение инфекции, вызванной респираторно-синцитиальным вирусом, вакциной на основе аденовируса
PE20081215A1 (es) Identificacion y caracterizacion de variantes de replicon de vhc con menor susceptibilidad a vhc-796, y metodos relacionados
PH12020551051A1 (en) Human antibodies to influenza hemagglutinin
RU2012120671A (ru) Рекомбинантный человеческий белок сс10 для лечения гриппа
CL2021002427A1 (es) Vector y método de tratamiento del síndrome de angelman
MX2023000734A (es) Virus vaccinia recombinante.
TR201902131T4 (tr) Enfeksiyöz bronşit virüsünün (IBV) doku tropizmini uzatan mutant diken proteini.
PL435261A1 (pl) Peptyd do stosowania w leczeniu lub zapobieganiu COVID-19
EA200500533A1 (ru) Пептидные производные - ингибиторы слияния при вич-инфекции
PL436491A1 (pl) Peptyd do stosowania w leczeniu lub zapobieganiu COVID-19
EA201290852A1 (ru) Комбинированная терапия, включающая антагонист ccr5, ингибитор протеазы вич-1 и фармакокинетический усилитель
PH12020551944A1 (en) Reverse peptide vaccine
ATE401392T1 (de) Subtypabgestimmte inaktivierte vollvirusvakzine zur behandlung von patienten mit hiv-infektion
EA200501569A1 (ru) Лечение или профилактика респираторных вирусных инфекций с использованием пептидов альфа-тимозина
MY207220A (en) Anti-hemagglutinin antibodies and methods of use thereof
AR122015A1 (es) Formulaciones de niclosamida y métodos de uso
EA202092732A1 (ru) АНТИТЕЛА, КОТОРЫЕ НАЦЕЛЕНЫ НА ГЛИКОПРОТЕИН gp120 ВИРУСА ИММУНОДЕФИЦИТА ЧЕЛОВЕКА (ВИЧ), И СПОСОБЫ ИХ ПРИМЕНЕНИЯ